NANOTECHNOLOGY IN CANCER DRUG DELIVERY: INNOVATIONS AND CLINICAL APPLICATIONS
Main Article Content
Keywords
Nanotechnology, Cancer, Drug Delivery, Nanocarriers, Clinical Applications
Abstract
Background and Objective: Traditional therapies are poorly specific and cause severe side effects and reduced efficacy in cancer treatment. Engineered nanocarriers for drug delivery are promising solutions provided by nanotechnology that can enhance the precision of drug delivery, reduce toxicity, and improve therapeutic outcomes. In this review, recent advances and clinical applications of nanotechnology for cancer drug delivery are explored.
Materials and Methods: Databases like PubMed, Scopus, and Web of Science were used for a systematic review of the literature. Studies published from 2014-2024 were included based on the criteria of nanocarriers' design, targeting strategies, and clinical evaluations. Preclinical, in vitro, and clinical studies were assessed for quality using standardized tools like the Cochrane Risk of Bias Tool and ARRIVE guidelines. Statistical analysis, performed using one-way ANOVA, validated significant findings with p-values <0.05.
Results: The review of 58 studies highlighted the dominance of liposomal nanocarriers (40%) and polymeric nanoparticles (19%). Tumor drug accumulation increased 2.5-fold and systemic toxicity was reduced by 40% with liposomal formulations. Dual drug delivery systems using polymeric nanoparticles exhibited a 60% improvement in tumor suppression. Gold nanoparticles showed 85% tumor ablation in clinical trials, while antibody-functionalized nanocarriers increased specificity by a factor of three. Statistical analysis confirmed the efficacy of nanocarrier-based systems, with consistent p-values <0.05 when compared to conventional therapies. Active targeting strategies with ligands and antibodies improved tumor-to-normal tissue ratios, whereas passive targeting through the enhanced permeability and retention (EPR) effect increased tumor drug accumulation by 20–30%.
Conclusion: Nanotechnology offers transformative potential in cancer therapy, enabling targeted, efficient, and safer drug delivery. Challenges to clinical translation should be addressed in future research by expanded trials, stimuli–responsive designs, and standardized protocols.
References
2. Jansman FG, Sleijfer DT, de Graaf JC, et al. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Safety. 2001 Apr;24:353-67.
3. Chemotherapy to Treat Cancer. (2022, August 23). Cancer.gov. https://www.cancer.gov/about-cancer/treatment/types/chemotherapy#:~:text=of%20your%20body-,Chemotherapy%20can%20cause%20side%20effects,after%20you%20have%20finished%20chemotherapy.&text=There%20are%20many%20ways%20you,the%20section%20on%20side%20effects.
4. Hull LC, Farrell D, Grodzinski P. Highlights of recent developments and trends in cancer nanotechnology research—View from NCI Alliance for Nanotechnology in Cancer. Biotechnology advances. 2014 Jul 1;32(4):666-78.
5. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nano-enabled medical applications. 2020 Nov 23:61-91.
6. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nature reviews Drug discovery. 2014 Nov;13(11):813-27.
7. Alavi M, Hamidi M. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug metabolism and personalized therapy. 2019 Mar 26;34(1):20180032.
8. Shi Y, van der Meel R, Chen X, Lammers T. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 2020;10(17):7921.
9. Desai N. Challenges in development of nanoparticle-based therapeutics. The AAPS journal. 2012 Jun;14(2):282-95.
10. Elumalai K, Srinivasan S, Shanmugam A. Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment. Biomedical Technology. 2024 Mar 1;5:109-22.
11. Paul S, Pathak H, Sharma HK. An overview on nanocarriers. Nanocarriers for drug-targeting brain tumors. 2022 Jan 1:145-204.
12. Sindhwani S, Syed AM, Ngai J, Kingston BR, Maiorino L, Rothschild J, MacMillan P, Zhang Y, Rajesh NU, Hoang T, Wu JL. The entry of nanoparticles into solid tumours. Nature materials. 2020 May;19(5):566-75.
13. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Advanced drug delivery reviews. 2013 Jan 1;65(1):36-48.
14. Rabaan AA, Bukhamsin R, AlSaihati H, Alshamrani SA, AlSihati J, Al-Afghani HM, Alsubki RA, Abuzaid AA, Al-Abdulhadi S, Aldawood Y, Alsaleh AA. Recent trends and developments in multifunctional nanoparticles for cancer theranostics. Molecules. 2022 Dec 7;27(24):8659.
15. Barenholz YC. Doxil®—The first FDA-approved nano-drug: Lessons learned. Journal of controlled release. 2012 Jun 10;160(2):117-34.
16. Yuan H, Guo H, Luan X, He M, Li F, Burnett J, Truchan N, Sun D. Albumin nanoparticle of paclitaxel (Abraxane) decreases while taxol increases breast cancer stem cells in treatment of triple negative breast cancer. Molecular pharmaceutics. 2020 Jun 2;17(7):2275-86.
17. Kröger AP, Paulusse JM. Single-chain polymer nanoparticles in controlled drug delivery and targeted imaging. Journal of controlled release. 2018 Sep 28;286:326-47.
18. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Frontiers in molecular biosciences. 2020 Aug 20;7:193.
19. Amreddy N, Babu A, Muralidharan R, Panneerselvam J, Srivastava A, Ahmed R, Mehta M, Munshi A, Ramesh R. Recent advances in nanoparticle-based cancer drug and gene delivery. Advances in cancer research. 2018 Jan 1;137:115-70.
20. Priester MI, Ten Hagen TL. Image-guided drug delivery in nanosystem-based cancer therapies. Advanced Drug Delivery Reviews. 2023 Jan 1;192:114621.
21. Bi J, Mo C, Li S, Huang M, Lin Y, Yuan P, Liu Z, Jia B, Xu S. Immunotoxicity of metal and metal oxide nanoparticles: from toxic mechanisms to metabolism and outcomes. Biomaterials science. 2023;11(12):4151-83.
22. Santhanakrishnan KR, Koilpillai J, Narayanasamy D. PEGylation in Pharmaceutical Development: Current Status and Emerging Trends in Macromolecular and Immunotherapeutic Drugs. Cureus. 2024 Aug;16(8).
23. Subhan MA, Yalamarty SS, Filipczak N, Parveen F, Torchilin VP. Recent advances in tumor targeting via EPR effect for cancer treatment. Journal of personalized medicine. 2021 Jun 18;11(6):571.
24. Aloss K, Hamar P. Recent preclinical and clinical progress in liposomal doxorubicin. Pharmaceutics. 2023 Mar;15(3):893.
25. Nakka NM, Rachamala HK, Angom RS, Indla NR, Dutta SK, Wang E, Bhattacharya S, Sainath AV, Babiker H, Pal K, Mukhopadhyay D. Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenocarcinoma. Materials Today Bio. 2024 Oct 1;28:101199.
26. Riley RS, Day ES. Gold nanoparticle‐mediated photothermal therapy: applications and opportunities for multimodal cancer treatment. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2017 Jul;9(4):e1449.
27. Khizar S, Elkalla E, Zine N, Jaffrezic-Renault N, Errachid A, Elaissari A. Magnetic nanoparticles: Multifunctional tool for cancer therapy. Expert opinion on drug delivery. 2023 Feb 1;20(2):189-204.
28. Marques AC, da Costa PC, Velho S, Amaral MH. Antibody-Functionalized Nanoparticles for Targeted Drug Delivery in Cancer Therapy. InHandbook of Cancer and Immunology 2023 Feb 22 (pp. 1-43). Cham: Springer International Publishing.
29. Begines B, Ortiz T, Pérez-Aranda M, Martínez G, Merinero M, Argüelles-Arias F, Alcudia A. Polymeric nanoparticles for drug delivery: Recent developments and future prospects. Nanomaterials. 2020 Jul 19;10(7):1403.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Aishwarya Alavandar
Senior resident, Sree Balaji Medical College and Hospital
Dr. Prathamesh V Pakale
MBBS, M.D. Pharmacology, Assistant Professor, Department of Pharmacology, Krishna Institute of Medical Sciences, Karad
Dr. M.A.Q. Ansari
Associate Professor of Orthopaedics, Yadgir Institute of Medical Sciences, Yadgiri, RGUHS, Bangalore
Dr. Mukti Sharma
Senior Scientist, Department of Molecular Biology & Biochemistry, SGRR Institute of Medical and Health Sciences, Dehradun, Uttarakhand
Dr. Santhosha Kulal
Assistant Professor, Department of Radiation Oncology, Sri Devaraj urs Academy of Higher Education and Research, Sri Devaraj urs Medical College, Tamaka, Kolar, Karnataka, India